Professor Sharon Lewin AO is the inaugural director of the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and Royal Melbourne Hospital; Professor of Medicine, the University of Melbourne; consultant infectious diseases physician, Alfred Hospital, Melbourne, Australia. The Doherty Institute has over 700 staff entirely focused on infection and immunity. The institute includes public health laboratories, clinicians, public health physicians and epidemiologists and fundamental discovery research.
Her research focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. Her laboratory has had extensive experience with supporting interventional clinical trials and has developed numerous quantitative assays for detection of low levels of HIV. Professor Lewin co-leads the laboratory research area for APPRISE and is a member of the executive leadership group.
Professor Lewin is an elected member of the governing council of the International AIDS Society and, in 2016, she was awarded the Peter Wills Medal from Research Australia.
In 2019, Professor Lewin was appointed as an Officer (AO) of the Order of Australia and, in 2014, she was named Melburnian of the Year.
Research Leader of
Theme Leader of
- Anticoagulation strategies in non–critically ill patients with Covid-19
- Nafamostat mesylate for treatment of COVID-19 in hospitalised patients: A structured, narrative review
- Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection
- Evaluation of 6 commercial SARS-CoV-2 serology assays detecting different antibodies for clinical testing and serosurveillance
- Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance
- Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
- Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study
- Maintaining strong foundations and building resilience: planning Australia’s path through the COVID-19 pandemic
- Leveraging the advances in HIV for COVID-19
- Isolation and rapid sharing of the 2019 novel coronavirus (SARS ‐CoV‐2) from the first patient diagnosed with COVID ‐19 in Australia
- Rapid research report – The most promising therapeutics for COVID-19
- Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19
- Developing research priorities for Australia’s response to infectious disease emergencies
- Is Australia prepared for the next pandemic?